LYNBROOK, N.Y., Sept. 13, 2012 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in Europe and Eurasia, today announced that Tom Wegman, President of BioSpecifics, will present at the upcoming UBS Global Life Sciences Conference at 1:30 pm EDT on Thursday, September 20, 2012 in New York, NY.
The live webcast of this presentation may be accessed under "Calendar of Events" in the Investor Relations section of BioSpecifics' website at www.biospecifics.com or at the link http://cc.talkpoint.com/ubsx001/091912a_im/?entity=41_RNQXBE6. A replay of the webcast will also be available on the Company's website following the presentation.
About BioSpecifics Technologies Corp.
BioSpecifics Technologies Corp. is a biopharmaceutical company that has developed injectable collagenase for twelve clinical indications. Currently, injectable collagenase is marketed as XIAFLEX® in the U.S. for the treatment of adult Dupuytren's contracture patients with a palpable cord by Auxilium Pharmaceuticals, Inc. (Auxilium) and is also in clinical development for the treatment of several additional promising indications. Auxilium has reported positive top-line results from two recently completed Phase III clinical trials for Peyronie's disease and is also testing XIAFLEX for frozen shoulder syndrome (adhesive capsulitis) and cellulite in Phase IIa and Phase Ib clinical trials, respectively. BioSpecifics is currently managing the clinical development of XIAFLEX for the treatment of human lipoma and canine lipoma, which are both in Phase II clinical trials. Auxilium has entered into three strategic partnershi
|SOURCE BioSpecifics Technologies Corp.|
Copyright©2012 PR Newswire.
All rights reserved